490 related articles for article (PubMed ID: 25788265)
21. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma.
Dayton TL; Gocheva V; Miller KM; Israelsen WJ; Bhutkar A; Clish CB; Davidson SM; Luengo A; Bronson RT; Jacks T; Vander Heiden MG
Genes Dev; 2016 May; 30(9):1020-33. PubMed ID: 27125672
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.
Taniguchi K; Sugito N; Kumazaki M; Shinohara H; Yamada N; Nakagawa Y; Ito Y; Otsuki Y; Uno B; Uchiyama K; Akao Y
Cancer Lett; 2015 Jul; 363(1):17-27. PubMed ID: 25818238
[TBL] [Abstract][Full Text] [Related]
23. SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
Tai WT; Hung MH; Chu PY; Chen YL; Chen LJ; Tsai MH; Chen MH; Shiau CW; Boo YP; Chen KF
Oncotarget; 2016 Apr; 7(16):22193-205. PubMed ID: 26959741
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
[TBL] [Abstract][Full Text] [Related]
25. Nuclear PKM2 expression, an independent risk factor for ER after curative resection of hepatocellular carcinoma.
Fan F; Wu H; Liu Z; Hou X; Chen W; Wang A; Lu Y
Biomed Pharmacother; 2016 Dec; 84():1858-1864. PubMed ID: 27894667
[TBL] [Abstract][Full Text] [Related]
26. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma.
Lu SX; Zhang CZ; Luo RZ; Wang CH; Liu LL; Fu J; Zhang L; Wang H; Xie D; Yun JP
Cancer Lett; 2017 Aug; 402():71-80. PubMed ID: 28577975
[TBL] [Abstract][Full Text] [Related]
27. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma.
Xu Q; Zhang M; Tu J; Pang L; Cai W; Liu X
Oncol Rep; 2015 Oct; 34(4):2054-64. PubMed ID: 26252254
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma.
Liu Y; Wu H; Mei Y; Ding X; Yang X; Li C; Deng M; Gong J
Sci Rep; 2017 Nov; 7(1):15294. PubMed ID: 29127353
[TBL] [Abstract][Full Text] [Related]
30. TSP50 promotes the Warburg effect and hepatocyte proliferation via regulating PKM2 acetylation.
Gao F; Zhang X; Wang S; Zheng L; Sun Y; Wang G; Song Z; Bao Y
Cell Death Dis; 2021 May; 12(6):517. PubMed ID: 34016961
[TBL] [Abstract][Full Text] [Related]
31. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species.
Yokoyama M; Tanuma N; Shibuya R; Shiroki T; Abue M; Yamamoto K; Miura K; Yamaguchi K; Sato I; Tamai K; Satoh K
Int J Oncol; 2018 Mar; 52(3):881-891. PubMed ID: 29393401
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of SR splicing-factor 5 knockdown by downregulating pyruvate kinase M2 in non-small cell lung cancer cells.
Yan J; Zhang D; Han Y; Wang Z; Ma C
J Cell Biochem; 2019 Oct; 120(10):17303-17311. PubMed ID: 31106485
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.
Wang Y; Zhang X; Zhang Y; Zhu Y; Yuan C; Qi B; Zhang W; Wang D; Ding X; Wu H; Cheng J
Cancer Biol Ther; 2015; 16(6):839-45. PubMed ID: 25970228
[TBL] [Abstract][Full Text] [Related]
34. Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo.
Yuan Q; Yu H; Chen J; Song X; Sun L
Exp Cell Res; 2018 Jan; 362(1):209-216. PubMed ID: 29155364
[TBL] [Abstract][Full Text] [Related]
35. Pyruvate kinase M2 regulates apoptosis of intestinal epithelial cells in Crohn's disease.
Tang Q; Ji Q; Xia W; Li L; Bai J; Ni R; Qin Y
Dig Dis Sci; 2015 Feb; 60(2):393-404. PubMed ID: 24817408
[TBL] [Abstract][Full Text] [Related]
36. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
[TBL] [Abstract][Full Text] [Related]
37. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
Jung Y; Jang YJ; Kang MH; Park YS; Oh SJ; Lee DC; Xie Z; Yoo HS; Park KC; Yeom YI
Mol Cells; 2013 Apr; 35(4):335-41. PubMed ID: 23515579
[TBL] [Abstract][Full Text] [Related]
38. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.
Dong T; Yan Y; Chai H; Chen S; Xiong X; Sun D; Yu Y; Deng L; Cheng F
Biomed Pharmacother; 2015 Feb; 69():277-84. PubMed ID: 25661370
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of Pyruvate Kinase M2 Inhibits Cell Proliferation, Metabolism, and Migration in Renal Cell Carcinoma.
Dey P; Son JY; Kundu A; Kim KS; Lee Y; Yoon K; Yoon S; Lee BM; Nam KT; Kim HS
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717694
[TBL] [Abstract][Full Text] [Related]
40. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
Shukla S; Rizvi F; Raisuddin S; Kakkar P
Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
